Prognostic value and nomograms of proximal margin distance in gastric cancer with radical distal gastrectomy

Jun Luo¹,²*, Yuming Jiang¹*, Xinhua Chen¹, Yuehong Chen¹, Jhang Lopsang Gurung¹, Tingyu Mou¹, Liying Zhao¹, Guoqing Lyu², Tuanjie Li¹, Guoxin Li¹, Jiang Yu¹

¹Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; ²Department of Gastrointestinal Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, China

*These authors contributed equally to this work.

Correspondence to: Jiang Yu. Department of General Surgery, Nanfang Hospital, Southern Medical University, North Guangzhou Road 1838, Guangzhou 510515, China. Email: balbc@163.com; Guoxin Li. Department of General Surgery, Nanfang Hospital, Southern Medical University, North Guangzhou Road 1838, Guangzhou 510515, China. Email: gzliguoxin@163.com; Tuanjie Li. Department of General Surgery, Nanfang Hospital, Southern Medical University, North Guangzhou Road 1838, Guangzhou 510515, China. Email: lituanj@mail2.sysu.edu.cn; Guoqing Lyu. Department of Gastrointestinal Surgery, Peking University Shenzhen Hospital, Lianhua Road 1120, Shenzhen 518036, China. Email: 365973269@qq.com.

Abstract

Objective: The proximal margin (PM) distance for distal gastrectomy (DG) of gastric cancer (GC) remains controversial. This study investigated the prognostic value of PM distance for survival outcomes, and aimed to combine clinicopathologic variables associated with survival outcomes after DG with different PM distance for GC into a prediction nomogram.

Methods: Patients who underwent radical DG from June 2004 to June 2014 at Department of General Surgery, Nanfang Hospital, Southern Medical University were included. The first endpoints of the prognostic value of PM distance (assessed in 0.5 cm increments) for disease-free survival (DFS) and overall survival (OS) were assessed. Multivariate analysis by Cox proportional hazards regression was performed using the training set, and the nomogram was constructed, patients were chronologically assigned to the training set for dates from June 1, 2004 to January 30, 2012 (n=493) and to the validation set from February 1, 2012 to June 30, 2014 (n=211).

Results: Among 704 patients with pTNM stage I, pTNM stage II, T1−2, T3−4, N0, differentiated type, tumor size ≤5.0 cm, a PM of (2.1−5.0) cm vs. PM≤2.0 cm showed a statistically significant difference in DFS and OS, while a PM>5.0 cm was not associated with any further improvement in DFS and OS vs. a PM of 2.1−5.0 cm. In patients with pTNM stage III, N1, N2−3, undifferentiated type, tumor size >5.0 cm, the PM distance was not significantly correlated with DFS and OS between patients with a PM of (2.1−5.0) cm and a PM≤2 cm, or between patients with a PM >5.0 cm and a PM of (2.1−5.0) cm, so there were no significant differences across the three PM groups. In the training set, the C-indexes of DFS and OS, were 0.721 and 0.735, respectively, and in the validation set, the C-indexes of DFS and OS, were 0.752 and 0.751, respectively.

Conclusions: It is necessary to obtain not less than 2.0 cm of PM distance in early-stage disease, while PM distance was not associated with long-term survival in later and more aggressive stages of disease because more advanced GC is a systemic disease. Different types of patients should be considered for removal of an individualized PM distance intra-operatively. We developed a universally applicable prediction model for accurately determining the 1-year, 3-year and 5-year DFS and OS of GC patients according to their preoperative clinicopathologic characteristics and PM distance.

Keywords: Gastric cancer; margin distance; nomograms; distal gastrectomy

Submitted Oct 26, 2019. Accepted for publication Apr 03, 2020.
doi: 10.21147/j.issn.1000-9604.2020.02.06
**Introduction**

Gastric cancer (GC) has become a significant cause of cancer-related deaths worldwide (1-3). Radical resection is still the only proven and potentially curative treatment for GC without distant metastasis (4,5). A range of proximal margin (PM) distance has been advocated for distal gastric adenocarcinoma in previous studies (6-10); however, the specific margin width remains debatable. To ensure radical resection of the tumor, some surgeons prefer to get a wider margin, but reducing the margin width during resection has been associated with better quality of life, easier digestive tract reconstruction and a lower incidence of complications. Therefore, it is imperative to identify optimal margins of excision to reduce postoperative recurrence and complications and to increase postoperative quality of life in patients with GC.

The aim of the current study was to assess the relationship between PM distance and clinicopathological variables and to evaluate the prognostic value of PM distance for disease-free survival (DFS) and overall survival (OS) in patients after radical distal gastrectomy (DG) in order to provide a reasonable reference for the surgeon to select a suitable PM distance intra-operatively. In addition, this study combined preoperative clinicopathologic variables associated with DFS and OS with PM distance into a prediction nomogram for GC based on the data from Department of General Surgery, Nanfang Hospital, Southern Medical University.

**Materials and methods**

**Patient population**

This retrospective study included 704 consecutive patients with gastric adenocarcinoma underwent treatment between June 1, 2004 to June 30, 2014 at Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China. The baseline characteristics for each variable are listed in Table 1. Among the patients, those who underwent DG with R0 resection were selected for analysis. To eliminate the interference of residual neoplasm in this study, patients with microscopic residual tumor (R1) and macroscopic residual tumor (R2) were excluded. We thoroughly and systematically analyzed the patients’ clinical basic data and clinicopathological parameters. The preoperative TNM stage and the final pathologic TNM stage were classified according to the AJCC Cancer Staging Manual, 7th Edition (11). During the study period, patients were followed up from the date of surgery until July 1, 2017 or their death. The follow-up period for survivors ranged from 5 to 133 months, with a mean period of 48 months. Each patient’s follow-up data were collected from hospital records.

**Margin analysis**

The distribution of PM distance in 0.5 cm increments is shown in Figure 1A. Margin distance was measured by surgeon within half an hour after the stomach cancer specimen was removed. The first objective was to evaluate the prognostic value of PM distance for DFS and OS after DG with R0 resection. DFS in this current study was defined as the time to recurrence at any site (such as anastomosis, gastric remnant, perigastric regional lymph nodes and distant metastasis to the pancreas, liver, peritoneum, or other sites). We also conducted multiple subgroup analysis based on PM distance in DFS and OS among different clinicopathological variables. We analyzed the survival of patients for the three intervals beyond which no apparent further increase in DFS and OS was observed (PM $\leq$ 1.0 cm vs. 1.1-1.5 cm vs. 1.6-2.0 cm; DFS, $P=0.168$; OS, $P=0.062$; Figure 1B), while the PM in 0.5 cm increments, these four groups showed a statistically significant difference in DFS and OS (PM $\leq$ 1.0 cm vs. 1.1-1.5 cm vs. 1.6-2.0 cm vs. 2.1-2.5 cm; DFS, $P=0.022$; OS, $P=0.003$; Figure 1B). Thus, the entire cohort was finally divided into three PM distance groups ($\leq$ 2.0 cm, 2.1-5.0 cm, and >5.0 cm).

**Construction of nomogram**

For nomogram construction and validation, we chronologically assigned patients from June 1, 2004 to January 31, 2012 to the training set (n=493) and patients from February 1, 2012 to June 30, 2014 to the validation set (n=211). The preoperative clinicopathologic characteristics and the PM distance in the training and validation set were evaluated. For the current study, 9 variables were included in the initial analysis: age, sex, carcinoembryonic antigen (CEA), carbohydrate antigen (CA)199, CA724, cT stage, cN stage, biopsy histology type
Variables were selected by the forward stepwise selection method using the Cox regression model. On the

Table 1 Clinicopathological features of gastric cancer patients (N=704)

| Variables                  | No. | %  |
|----------------------------|-----|----|
| Age (year)                 |     |    |
| ≤60                        | 469 | 66.6|
| >60                        | 235 | 33.4|
| Sex                        |     |    |
| Male                       | 458 | 65.1|
| Female                     | 246 | 34.9|
| Clinical T stage           |     |    |
| T1                         | 90  | 12.8|
| T2                         | 123 | 17.5|
| T3                         | 126 | 17.9|
| T4                         | 365 | 51.8|
| Clinical N stage           |     |    |
| N0                         | 323 | 45.9|
| N1                         | 181 | 25.7|
| N2                         | 135 | 19.2|
| N3                         | 65  | 9.2 |
| CEA (µg/L)                 |     |    |
| <5                         | 648 | 92.0|
| ≥5                         | 56  | 8.0 |
| CA199 (U/mL)               |     |    |
| <37                        | 614 | 87.2|
| ≥37                        | 90  | 12.8|
| CA724 (U/mL)               |     |    |
| <6.9                       | 624 | 88.6|
| ≥6.9                       | 80  | 11.4|
| PM (cm)                    |     |    |
| 0−2.0                      | 90  | 12.8|
| 2.1−5                      | 462 | 65.6|
| >5                         | 152 | 21.6|
| Biopsy histology           |     |    |
| Differentiated             | 236 | 33.5|
| Undifferentiated           | 468 | 66.5|
| Postoperative histology    |     |    |
| Differentiated             | 227 | 32.2|
| Undifferentiated           | 477 | 67.8|
| Pathologic T stage         |     |    |
| <T2                        | 216 | 30.7|
| T2                         | 81  | 11.5|
| T3                         | 62  | 8.8 |
| T4                         | 345 | 49.0|

Table 1 (continued)

| Variables                  | No. | %  |
|----------------------------|-----|----|
| Pathologic N stage         |     |    |
| N0                         | 359 | 50.9|
| N1                         | 106 | 15.1|
| N2                         | 106 | 15.1|
| N3                         | 133 | 18.9|
| Pathologic TNM stage       |     |    |
| I                          | 246 | 34.9|
| II                         | 167 | 23.7|
| III                        | 291 | 41.3|
| Tumor size (cm)            |     |    |
| ≤5                         | 524 | 74.4|
| >5                         | 180 | 25.6|

CEA, carcinoembryonic antigen; CA, carbohydrate antigen; PM, proximal margin.

Figure 1 Discrepancies of proximal margin (PM) and its relationship with disease-free survival (DFS) and overall survival (OS) of gastric cancer patients. (A) Distribution of PM distance in 0.5 cm increments; (B) Kaplan-Meier analysis of DFS (P=0.022) and OS (P=0.003) according to PM distance (0−1.0, 1.1−1.5, 1.6−2.0, 2.1−2.5 cm).

and PM. Variables were selected by the forward stepwise selection method using the Cox regression model. On the
basis of the predictive model with the prognostic factors, a nomogram was constructed for predicting 1-year, 3-year and 5-year DFS and OS.

Validation of nomogram

Nomogram validation consisted of a discrimination and calibration curve. Discrimination was assessed using the concordance index (C-index). To do so, a relatively unbiased estimate was obtained with the bootstrap method. The data were randomly drawn with replacement from the original data set, and the parameters were recalculated. The C-index was then computed using the new parameters in the bootstrap random samples. After grouping of the nomogram predicted survival by decibel, calibration was carried out by comparing the means of predicted survival with actual survival evaluated with the Kaplan-Meier method.

Statistical analysis

DFS and OS were evaluated using the Kaplan-Meier method. A multivariate predictive model was constructed using a Cox proportional hazards model based on univariate and multivariate Cox regression analyses of risk factors associated with DFS and OS, and P<0.05 was considered statistically significant. All calculations were performed with SPSS version 20.0 (IBM Inc., New York, USA) and R software version 3.4.0 (http://www.r-project.org) with the design and survival packages. Survival analysis was performed with the “survival” package. Multivariate Cox regression, nomograms and calibration plots were generated with the “rms” package. Comparisons between C-indexes were performed with the “Hmisc” package. Decision curve analysis was performed with the function of “dca.R”. Reported statistical significance levels were all two-sided. The statistical significance level was set at 0.05.

Results

Entire cohort analysis

The PM distances were divided into three groups for analysis (PM $\leq$ 2.0 cm, n=90; PM: 2.1−5.0 cm; n=462, and PM>5.0 cm, n=152). For 704 patients, Kaplan-Meier analysis showed an extended survival time, while patients with a PM of 2.1−5.0 cm and those with a PM $\leq$ 2.0 cm demonstrated significant differences in DFS and OS (P<0.001 for both) (Figure 2A,E). However, the difference was not significant when the two groups were compared to those with a PM of 2.1−5.0 cm vs. a PM>5.0 cm (P=0.181 and P=0.492, respectively) (Figure 2A,E).

Figure 2 Kaplan-Meier analysis of disease-free survival (DFS) and overall survival (OS) with different pTNM stages. (A) DFS according to: (a) entire cohort (PM 2.1−5.0 cm vs. $\leq$2.0 cm, P=0.001), (b) stage I (PM 2.1−5.0 cm vs. $\leq$2.0 cm, P<0.001), (c) stage II (PM 2.1−5.0 cm vs. $\leq$2.0 cm, P=0.022), and (d) stage III (PM$\leq$2.0 cm vs. 2.1−5.0 cm vs. >5.0 cm, P=0.059); (B) OS according to: (a) entire cohort (PM 2.1−5.0 cm vs. $\leq$2.0 cm, P<0.001), (b) stage I (PM 2.1−5.0 cm vs. $\leq$2.0 cm, P<0.001), (c) stage II (PM 2.1−5.0 cm vs. $\leq$2.0 cm, P=0.027), and (d) stage III (PM$\leq$2.0 cm vs. 2.1−5.0 cm vs. >5.0 cm, P=0.064).

© Chinese Journal of Cancer Research. All rights reserved. www.cjercn.org Chin J Cancer Res 2020;32(2):186-196
**Subgroup stratification analysis**

Among patients with pTNM stage I and TNM stage II disease, a PM of 2.1−5.0 cm vs. PM≤2.0 cm showed a statistically significant difference in DFS (P<0.001 and P=0.022, respectively) (Figure 2B,C) and OS (P<0.001 and P=0.027, respectively) (Figure 2F,G), while a PM>5.0 cm was not associated with any further improvement in DFS (P=0.419 and P=0.346, respectively) and OS (P=0.749 and P=0.357, respectively) vs. a PM of 2.1−5.0 cm. In patients with pTNM stage III disease, the PM distance was not significantly correlated with DFS and OS between patients with a PM of 2.1−5.0 cm and a PM≤2 cm, or between patients with a PM>5.0 cm and a PM of 2.1−5.0 cm, so there were no significant differences across the PM≤2.0 cm vs. PM of 2.1−5.0 cm vs. PM>5.0 cm (P=0.059 and P=0.064, respectively) (Figure 2D,H).

Patients in the subgroups of T1−2 stage and T3−4 stage showed close correlations with DFS (P<0.001 and P=0.003, respectively) (Figure 3Aa,b) and OS (P<0.001 and P=0.003, respectively) (Figure 3Ba,b) between a PM of 2.1−5.0 cm and a PM≤2.0 cm; however, there was no significant association with DFS (P=0.237 and P=0.149, respectively) (Figure 3Aa,b) and OS (P=0.435 and P=0.369, respectively) (Figure 3Ba,b) between PM>5.0 cm and a PM of 2.1−5.0 cm. In survival analysis of patients in the subgroup of N0 stage, there was a statistical difference in DFS (P<0.001) and OS (P<0.001) between a PM of 2.1−5.0 cm and PM≤2.0 cm (Figure 3Ac,Bc), and there were no statistically significant differences for DFS (P=0.237 and P=0.149, respectively) (Figure 3Aa,b) and OS (P=0.435 and P=0.369, respectively) (Figure 3Ba,b) between PM>5.0 cm and a PM of 2.1−5.0 cm. In contrast, with regard to the correlation between long-term survival and N1 and N2−N3 stage, a statistical difference in DFS (P=0.149 and P=0.079, respectively) and OS (P=0.220 and P=0.092, respectively) was not observed (Figure 3Ad,e, 3Bd,e). For the subgroups of tumor size and postoperative histology type, both patients with a tumor size ≤5.0 cm and differentiated type disease showed a significant difference.

**Figure 3** Kaplan-Meier analysis of disease-free survival (DFS) and overall survival (OS) with different subgroup stratifications. (A) DFS according to: (a) T1−2 stage (PM 2.1−5.0 cm vs. ≤2.0 cm, P<0.001), (b) T3−4 stage (PM 2.1−5.0 cm vs. ≤2.0 cm, P=0.003), (c) N0 stage (PM 2.1−5.0 cm vs. ≤2.0 cm, P<0.001), (d) N1 stage (PM≤2.0 cm vs. 2.1−5.0 cm vs. >5.0 cm, P=0.149), (e) N2−3 stage (PM≥2.0 cm vs. 2.1−5.0 cm vs. >5.0 cm, P=0.079), (f) differentiated type (PM 2.1−5.0 cm vs. ≤2.0 cm, P<0.001), (g) undifferentiated type (PM≤2.0 cm vs. 2.1−5.0 cm vs. >5.0 cm, P=0.144), (h) tumor size ≤5.0 cm (PM 2.1−5.0 cm vs. ≤2.0 cm, P=0.001), and (i) tumor size >5.0 cm (PM≤2.0 cm vs. 2.1−5.0 cm vs. >5.0 cm, P=0.167); (B) OS according to: (a) T1−2 stage (PM 2.1−5.0 cm vs. ≤2.0 cm, P<0.001), (b) T3−4 stage (PM 2.1−5.0 cm vs. ≤2.0 cm, P=0.003), (c) N0 stage (PM 2.1−5.0 cm vs. ≤2.0 cm, P<0.001), (d) N1 stage (PM≤2.0 cm vs. 2.1−5.0 cm vs. >5.0 cm, P=0.220), (e) N2−3 stage (PM≥2.0 cm vs. 2.1−5.0 cm vs. >5.0 cm, P=0.092), (f) differentiated type (PM 2.1−5.0 cm vs. ≤2.0 cm, P<0.001), (g) undifferentiated type (PM≤2.0 cm vs. 2.1−5.0 cm vs. >5.0 cm, P=0.588), (h) tumor size ≤5.0 cm (PM 2.1−5.0 cm vs. ≤2.0 cm, P<0.001), and (i) tumor size >5.0 cm (PM≤2.0 cm vs. 2.1−5.0 cm vs. >5.0 cm, P=0.069).
when the two subgroups were compared with a PM of 2.1–5.0 cm and PM≤2.0 cm in DFS (P<0.001 and P<0.001, respectively) and OS (P<0.001 and P<0.001, respectively) (Figure 3Af,h,3Bf,h); however, there remained a negative association between a PM>5.0 cm and a PM of 2.1–5.0 cm for DFS (P=0.075 and P=0.139, respectively) and OS (P=0.263 and 0.476, respectively). The subgroups with a tumor size >5.0 cm and undifferentiated type disease, which showed a similar survival curve, exhibited an insignificant difference between PM and long-term survival for DFS (P=0.167 and P=0.144, respectively) and OS (P=0.069 and P=0.588, respectively) (Figure 3Ag,i,3Bg,i).

**Entire cohort cox regression analysis**

Table 2 documents the results of multivariate Cox regression analyses for DFS and OS. Age, pT, pN, tumor size and PM were correlated with significantly worse survival. The Cox proportional hazards model indicated that pT, pN and pM were independent prognostic factors for DFS and OS and that age was also a prognostic factor for OS.

**Prediction model**

After examination and transformation of the preoperative clinicopathologic variables to fit in the Cox regression model, variables were selected by the forward stepwise selection method (P<0.05). Table 3 lists the selected variables with hazard ratios. The PM, cT, cN, CEA and CA199 are high hazard ratios of DFS, and except for these ratios, age is particular for OS.

Figure 4A shows the nomogram predicting 1-year, 3-year and 5-year DFS and OS was constructed based on the selected variables with hazard ratios. The nomogram can estimate the probability of survival by adding up the points identified on the points scale for each variable. The total points projected to the bottom scale indicate the probability of 1-year, 3-year and 5-year survival.

In the training set, the C-indexes of DFS and OS were 0.721 (95% CI, 0.686–0.757) and 0.735 (95% CI, 0.698–0.773), respectively. In the validation set, the C-indexes of DFS and OS were 0.752 (95% CI, 0.703–0.801) and 0.751 (95% CI, 0.686–0.817), respectively. Figure 4B shows the calibration curve of the nomogram, where the x-axis is the predicted survival calculated by the nomogram, and the y-axis is the actual survival analyzed by the Kaplan-Meier method. The solid line represents the ideal reference line where predicted survival corresponds with actual survival. The calibration of the model seemed to yield accurate and useful predictions of 1-year, 3-year and 5-year survival in GC patients.

**Table 2** Multivariate Cox regression analysis of risk factors associated with DFS and OS

| Characteristics | DFS | OS |
|----------------|-----|----|
|                | HR  | 95% CI      | P  | HR  | 95% CI      | P  |
| Age            | 1.216 | 0.947–1.563 | 0.125 | 1.483 | 1.116–1.969 | 0.007 |
| pT             |     | <0.001 |     |     | <0.001 |     |
| T1             | Ref | Ref    | Ref |     | Ref    | Ref |
| T2             | 1.150 | 0.634–2.085 | 1.150 | 1.239 | 0.629–2.443 | 0.536 |
| T3             | 1.626 | 0.893–2.963 | 0.112 | 1.763 | 0.873–3.558 | 0.114 |
| T4             | 4.029 | 2.073–6.007 | <0.001 | 3.809 | 2.379–6.089 | <0.001 |
| pN             |     | <0.001 |     |     | <0.001 |     |
| N0             | Ref | Ref    | Ref |     | Ref    | Ref |
| N1             | 1.085 | 0.720–1.556 | 0.773 | 1.284 | 0.822–2.006 | 0.272 |
| N2             | 1.146 | 0.791–1.661 | 0.471 | 1.319 | 0.859–2.025 | 0.206 |
| N3             | 2.257 | 1.615–3.156 | <0.001 | 3.042 | 2.067–4.447 | <0.001 |
| Tumor size     | 1.140 | 0.875–1.485 | 0.332 | 1.017 | 0.750–1.379 | 0.914 |
| PM (cm)        |     | <0.001 |     |     | <0.001 |     |
| 0–2.0          | Ref | Ref    | Ref |     | Ref    | Ref |
| 2.1–5.0        | 0.508 | 0.372–0.693 | <0.001 | 0.470 | 0.329–0.670 | <0.001 |
| >5.0           | 0.408 | 0.275–0.604 | <0.001 | 0.433 | 0.279–0.672 | <0.001 |

DFS, disease-free survival; OS, overall survival; PM, proximal margin; HR, hazard ratio; 95% CI, 95% confidence interval.
Table 3 Training set of multivariate Cox regression analysis

| Characteristics | DFS          | OS          |
|-----------------|--------------|-------------|
|                 | HR 95% CI    | P           | HR 95% CI    | P           |
| Age             | 2.785 1.908–4.056 | <0.001 | 1.524 1.093–2.125 | 0.013 |
| CEA             | 1.584 1.114–2.254 | 0.011 | 1.826 1.250–2.669 | 0.002 |
| T1              | <0.001       | 0.008      | T2            | 0.673 0.343–1.321 | 0.250 | 0.761 0.362–1.602 | 0.473 |
| T3              | 1.245 0.678–2.285 | 0.480 | 1.204 0.605–2.396 | 0.596 |
| T4              | 2.056 1.214–3.482 | 0.007 | 1.799 0.983–3.292 | 0.057 |
| N0              | <0.001       | <0.001     | N1            | 1.079 0.727–1.601 | 0.707 | 1.418 0.910–2.207 | 0.123 |
| N2              | 1.789 1.218–2.627 | 0.003 | 1.777 1.144–2.761 | 0.010 |
| N3              | 2.811 1.797–4.396 | <0.001 | 3.273 1.955–5.478 | <0.001 |
| PM (cm)         | <0.001       | 0.012      | T3            | 1.245 0.678–2.285 | 0.480 | 1.204 0.605–2.396 | 0.596 |
| 0–2.0           | 0.510 0.348–0.764 | 0.001 | 0.554 0.359–0.855 | 0.008 |
| >5.0            | 0.429 0.273–0.673 | <0.001 | 0.486 0.292–0.810 | 0.006 |

CEA, carcinoembryonic antigen; CA, carbohydrate antigen; PM, proximal margin; DFS, disease-free survival; OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval.

Figure 4 Nomogram and its calibration of disease-free survival (DFS) and overall survival (OS) of gastric cancer patients. (A) Nomogram predicting 1-year, 3-year and 5-year DFS (a) and OS (b) that was constructed based on selected variables with hazard ratios; (B) Calibration of nomogram in training set (a,c) and validation set (b,d). (a,b) DFS; (c,d) OS.

Discussion

For decades, scholars have advocated resection of greater than 6 cm to attain an adequate margin of resection in gastrectomy for cancer (9), which is in agreement with other reports advocating for wide gross resection to
decrease the risk of positive margins and postoperative recurrence (12), especially for early-stage GC (13,14). For the resection margin of GC, the latest National Comprehensive Cancer Network (NCCN) practice guidelines dictate >4 cm for the gross tumor (15). The Japanese Gastric Cancer Treatment Guidelines advise that a >2 cm margin should be obtained for T1 tumors and 3–5 cm for T2–T4 tumors, depending on the growth pattern (16). To obtain an adequate PM, many surgeons insist on a total gastrectomy (TG) rather than a subtotal gastrectomy (SG) for GCs located in the middle-third of the stomach (17); however, surgeons may perform SG according to their own clinical experience and subjective judgment, taking into the account the results of intraoperative frozen-section examination that were established in order to achieve R0 resection. To determine the optimal surgical procedure for middle-third GC, TG or SG, previous studies have suggested that SG can be safely performed, resulting in a better nutritional status and quality of life (18-20), and both procedures have demonstrated similar long-term survival (20-23). Currently, some studies even suggest that the achievement of clear margins is sufficient for patients. All of these arguments result in inconsistencies of margin of resection in gastrectomy (24-26). In short, there are no established guidelines for the length of the resection margin.

This study provides a good reference for surgeons during gastrectomy, on a statistical basis, concerning decisions about the PM distance. In an analysis of the entire cohort, patients with a PM of 2.1–5.0 cm demonstrated significantly greater recurrence and long-term survival rates than patients with PM≤2.0 cm, while those with a PM>5.0 cm did not display significantly extended survival. Significant differences in recurrence and the long-term survival rate were found between patients with TNM stage I and II with a resection margin distance of less than or greater than 2.0 cm; however, the PM distance showed no significant correlation with the recurrence rate or the long-term survival rate in TNM stage III patients if the resection margin was negative. Significant differences were noted with a PM of 2.1–5.0 cm vs. PM≤2.0 cm in the survival curve, especially in the subgroups of T stage (T1–2, T3–4), N0 stage, differentiated type disease and tumor size ≤5.0 cm. The remainder of the subgroups showed that a larger PM was not associated with additional survival benefits, as long as the surgeon ensured an R0 resection margin.

Our results are similar to those of Squires et al., who proposed that a PM>3.0 cm was associated with improved survival in patients with TNM stage I disease, while the PM distance was not associated with the recurrence rate or the long-term survival rate in advanced GC (7). There was a little information in this study to support the role of PM length in gastrectomy because the PM distance was not related to survival in cases of more advanced TNM stage III. Several studies have reported that patients with a more aggressive stage may not necessarily benefit from a negative margin, as there is no significant difference in recurrence and survival between patients with R0 and R1 resection (26-29). We can deduce that a more advanced stage of GC is more than a local disease and that the tumor stage of patients is more strongly correlated with the prognosis than the margin of excision. In other words, more advanced-stage tumors indicate the presence of systemic disease.

The intra-operative PM distance status should be determined by tumor characteristics, such as the subgroups of TNM stage, T stage, N stage, tumor size and histology type (26-29). There is no doubt that tumor size also affects the resection margin in SG, and to achieve negative margin status, tumor size should be considered as an important indicator for evaluation of the prognosis of GC (30). From the analysis of subgroups performed in the current study, it may be more meaningful to obtain a sufficient PM distance in early-stage disease, whereas PM distance was not associated with long-term survival in later- and aggressive-staged tumors. This result suggests that postoperative survival of such tumors may be associated with the particular biological characteristics of the tumor, rather than the surgical operation and margin of excision. Consequently, the surgeon should select patients based on the stage of the tumor and its biological characteristics, and then they can try their best to minimize the margin of excision as much as possible on the premise of ensuring an appropriate safety margin of excision, with the primary objective of improving the patient’s quality of life and postoperative nutritional status. Especially for some cases, SG rather than TG is perhaps the best option for tumors located in the middle-third of the stomach. In addition, intraoperative frozen sections should become a necessity when it is difficult to determine the status of the resection margin.

In this context, we created a simple but comprehensive survival prediction model for individual patients with different preoperative variables after radical DG. PM length was identified as an independent prognostic factor in the current study. However, other preoperative factors such as age, sex, CEA, CA199, CA724, cT, cN and biopsy histology type could be used for predicting individualized survival. Nomograms have been developed to quantify risk
by combining prognostic factors in different diseases (31-35), which support the clinical reference value of this study. Preoperative examination data can be acquired using gastroscopy, endoscopic ultrasonography and computed tomography. Preoperative accurate diagnosis of the T and N stages and the collection of other preoperative clinical data in GC are important to permit tailored therapy to the extent of the excision margin during gastrectomy. Patients with GC should routinely have a set of serum tumor markers evaluated preoperatively, including CEA, CA199 and CA724, because elevated serum tumor markers are generally associated with recurrence and poor long-term survival (36,37). Among the three markers examined in this study, preoperative elevated CA199 and CEA were independent risk factors for reduced patient survival in a multivariate analysis when co-analyzed with CA724.

A recent study showed that for most colorectal cancer patients, “distant metastasis” originates from primary tumors, independent of any lymph node metastasis (38). A study led by Massachusetts General Hospital (MGH) investigators found that the traditional mode of spread of cancer cells — from the primary tumor, through nearby lymph nodes to other organs — may not apply in all cases (39). Thus, combined with the results regarding the appropriate margin of excision, I imagine that in some specific stages of GC, it may be possible to only perform local resection without (or with only limited) lymph node dissection in the future.

The conclusions of this analysis are limited by the single-institution and retrospective design of the study. The nomogram validation consisted of discrimination and calibration, but it lacked an additional external validation group. One key limitation of this analysis is that the number of patients with PM ≤ 2.0 cm was relatively small, which weakened the conclusion of the study. Margin distance was measured intraoperative by surgeon within half an hour once after the stomach cancer specimen removed, which is maximally reflect the intraoperative measurement precisely. However, the decreased measurement of the margin length of the resected specimen from in vivo tissue should be taken into account (40-42). Therefore, the actual length of the PM distance is slightly longer than that reported in the results of this analysis.

Conclusions

According to the results of subgroup analysis, different types of patients require removal of individualized margin lengths. It is necessary to obtain not less than 2.0 cm of PM distance in early-stage disease, while PM distance was not associated with long-term survival in later and more aggressive stages of disease because more advanced GC is a systemic disease. We developed and validated a nomogram predicting 1-year, 3-year and 5-year DFS and OS after radical DG for GC including PM length. We expect that our analysis of this cohort and our prediction model will provide a valuable reference tool for assessing prognosis in GC patients and may complement the existing clinical practice guidelines.

Acknowledgements

This study was supported by Grant of Wu Jieping Medical Funding (No. 320.2710.1819).

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3. GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol Hepatol 2020;5:42-54.
4. Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-49.
5. Yu J, Huang C, Sun Y, et al. Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: The CLASS-01 randomized clinical trial. JAMA 2019;321:1983-92.
6. Postlewait LM, Maithel SK. The importance of surgical margins in gastric cancer. J Surg Oncol 2016;113:277-82.
7. Squires MH 3rd, Kooby DA, Poultsides GA, et al. Is
it time to abandon the 5-cm margin rule during resection of distal gastric adenocarcinoma? A multi-institution study of the U.S. Gastric Cancer Collaborative. Ann Surg Oncol 2015;22:1243-51.

8. Ito H, Clancy TE, Osteen RT, et al. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? J Am Coll Surg 2004;199:880-6.

9. Bozzetti F, Bonfanti G, Bufalino R, et al. Adequacy of margins of resection in gastrectomy for cancer. Ann Surg 1982;196:685-90.

10. Ohe H, Lee WY, Hong SW, et al. Prognostic value of the distance of proximal resection margin in patients who have undergone curative gastric cancer surgery. World J Surg Oncol 2014;12:296.

11. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York: Springer, 2010.

12. Woo JW, Ryu KW, Park JY, et al. Prognostic impact of microscopic tumor involved resection margin in advanced gastric cancer patients after gastric resection. World J Surg 2014;38:439-46.

13. Papachristou DN, Agnanti N, D’Agostino H, et al. Histologically positive esophageal margin in the surgical treatment of gastric cancer. Am J Surg 1980;139:711-3.

14. Papachristou DN, Fortner JG. Local recurrence of gastric adenocarcinomas after gastrectomy. J Surg Oncol 1981;18:47-53.

15. National Comprehensive Cancer Network. Gastric Cancer (Version 1. 2014). Available online: http://www.nccn.org/professionals/physicianls/pdf/gastric.pdf

16. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014(ver. 4). Cancer 2017;20:1-19.

17. Clark CJ, Thirlby RC, Picozzi V Jr., et al Current problems in surgery: gastric cancer. Curr Probl Surg 2006;43:566-670.

18. Bozzetti F, Marubini E, Bonfanti G, et al. Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. The Italian Gastrointestinal Tumor Study Group. Ann Surg 1997;226:613-20.

19. Goto H, Kanaji S, Otsubo D, et al. Comparison of total versus subtotal gastrectomy for remnant gastric cancer. Langenbecks Arch Surg 2019;404:753-60.

20. Ji X, Yan Y, Bu ZD, et al. The optimal extent of gastrectomy for middle-third gastric cancer: distal subtotal gastrectomy is superior to total gastrectomy in short-term effect without sacrificing long-term survival. BMC cancer 2017;17:345.

21. Lee JH, Kim YL. Which is the optimal extent of resection in middle third gastric cancer between total gastrectomy and subtotal gastrectomy? J Gastric Cancer 2010;10:226-33.

22. Jang YJ, Park MS, Kim JH, et al. Advanced gastric cancer in the middle one-third of the stomach: Should surgeons perform total gastrectomy? J Surg Oncol 2010;101:451-6.

23. Bozzetti F, Marubini E, Bonfanti G, et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999;230:170-8.

24. Lee CM, Jee YS, Lee JH, et al. Length of negative resection margin does not affect local recurrence and survival in the patients with gastric cancer. World J Gastroenterol 2014;20:10518-24.

25. Postlewait LM, Squires MH 3rd, Kooby DA, et al. The importance of the proximal resection margin distance for proximal gastric adenocarcinoma: A multi-institutional study of the US Gastric Cancer Collaborative. J Surg Oncol 2015;112:203-7.

26. Lee JH, Ahn SH, Park DJ, et al. Clinical impact of tumor infiltration at the transected surgical margin during gastric cancer surgery. J Surg Oncol 2012;106:772-6.

27. Sun Z, Li DM, Wang ZN, et al. Prognostic significance of microscopic positive margins for gastric cancer patients with potentially curative resection. Ann Surg Oncol 2009;16:3028-37.

28. Bickenbach KA, Gonen M, Strong V, et al. Association of positive transection margins with gastric cancer survival and local recurrence. Ann Surg Oncol 2013;20:2663-8.

29. Deng J, Zhang R, Pan Y, et al. Tumor size as a recommendable variable for accuracy of the prognostic prediction of gastric cancer: a retrospective analysis of 1,521 patients. Ann Surg Oncol 2015;22:565-72.
31. Woo Y, Son T, Song K, et al. A novel prediction model of prognosis after gastrectomy for gastric carcinoma: development and validation using asian databases. Ann Surg 2016;264:114-20.
32. Han DS, Suh YS, Kong SH, et al. Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer. J Clin Oncol 2012;30:3834-40.
33. Gold JS, Gönen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009;10:1045-52.
34. Kattan MW, Stapleton AM, Wheeler TM, et al. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997;79:528-37.
35. Carmona-Bayonas A, Jiménez-Fonseca P, Lamarca Á, et al. Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: The GETNE-TRASGU study. J Clin Oncol 2019;37:2571-80.
36. Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association.

Cite this article as: Luo J, Jiang Y, Chen X, Chen Y, Gurung JL, Mou T, Zhao L, Lyu G, Li T, Li G, Yu J. Prognostic value and nomograms of proximal margin distance in gastric cancer with radical distal gastrectomy. Chin J Cancer Res 2020;32(2):186-196. doi: 10.21147/j.issn.1000-9604.2020.02.06

Gastric Cancer 2014;17:26-33.
37. Huang C, Liu Z, Xiao L, et al. Clinical significance of serum CA125, CA19-9, CA72-4, and fibrinogen-to-lymphocyte ratio in gastric cancer with peritoneal dissemination. Front Oncol 2019;9:1159.
38. Naxerova K, Reiter JG, Brachtel E, et al. Origins of lymphatic and distant metastases in human colorectal cancer. Science 2017;357:55-60.

39. Massachusetts General Hospital. Lymph node metastases may not always be the source of cancer’s spread to other organs: Study finds two distinct patterns of metastatic spread in human colorectal cancer. ScienceDaily 2017. Available online: https://www.sciencedaily.com/releases/2017/07/170706143122.htm
40. Wang L, Shen J, Song X, et al. A study of the lengthening and contractility of the surgical margins in digestive tract cancer. Am J Surg 2004;187:452-5.
41. Weese JL, O’Grady MG, Ottery FD. How long is the five centimeter margin? Surg Gynecol Obstet 1986;163:101-3.
42. Goldstein N, Soman A, Sacksner J. Disparate surgical margin length of colorectal resection specimens between in vivo and in vitro measurement. The effects of surgical resection and formalin fixation on organ shrinkage. Am J Clin Pathol 1999;111:349-51.